Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDVO.L Regulatory News (DVO)

  • There is currently no data for DVO

Trading Update

17 Jan 2020 07:00

RNS Number : 0947A
Devro PLC
17 January 2020
 

For immediate release 17 January 2020

Devro plc

 

Trading update

 

Devro plc ("Devro" or the "Group"), one of the world's leading manufacturers of collagen products for the food industry, issues the following trading update for the year ended 31 December 2019.

 

Full year edible collagen volumes were flat, with the Group delivering overall volume growth of 1% in the second half ("H2"). Slightly lower than anticipated H2 volumes, less favourable country mix combined with a smaller than expected FX benefit due to the strengthening of sterling means we now expect to report underlying operating profit for the year in the range of £39 - £40 million1.

 

Devro continues to execute its growth plans as set out in its "3Cs strategy", defending and building upon its strong market positions in mature markets2 and targeting to increase its share in emerging markets3. After a slower start in the first half of 2019 overall volumes in emerging markets grew 13% in the second half and 7% for the full year. Whilst overall volumes in North America grew 7%, growth during Q4 was not as strong as expected, specifically impacted by a longer than anticipated Christmas shutdown at a key customer. Market conditions in Japan and Europe continued to be challenging as previously guided. In Europe, we saw weak market sentiment, with lower promotional activity due to higher pork prices and the impact of de-stocking by some of our distributor partners, which we expect to continue into H1 2020. As a result, overall sales in mature markets declined 3% in the year.

 

Cost saving initiatives continued to deliver well and we will achieve £7m savings in FY 2019. Leverage at the year-end improved following positive working capital movements and we expect to report covenant net debt / covenant EBITDA of less than 2x as at 31 December 2019.

 

Our proposed plans for the closure of the Bellshill site in Scotland remain on track.

 

In 2020 we expect to achieve strong volume growth in emerging markets. In our mature markets we expect good volume growth in the North American snacking market and, whilst we anticipate a continuation of the challenging market conditions in Europe (particularly in the first half of 2020), we expect overall Group volumes to be ahead of 2019.

 

Devro will announce its results for the year ended 31 December 2019 on 4 March 2020.

 

 

Contacts:

 

Devro plc

Rutger Helbing

Chief Executive Officer

Tel: 020 3865 7637

Jackie Callaway

Chief Financial Officer

 

 

FTI Consulting

Richard Mountain / Nick Hasell

 

Tel: 020 3727 1340

1 Unaudited

2 Devro mature markets include: North America, Continental EU, UK & Ireland, Japan, Australia & NZ

3 Devro emerging markets include: Latin America, Russia & East, Middle East & Africa, South East Asia, China

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTSFIFUMESSEDF
Date   Source Headline
29th Nov 20225:23 pmRNSDirector/PDMR Shareholding
29th Nov 20225:11 pmRNSForm 8.3 - Devro Plc
29th Nov 20223:28 pmRNSForm 8.3 - Devro plc
29th Nov 20223:24 pmBUSForm 8.3 - DEVRO PLC
29th Nov 20222:34 pmRNSForm 8.3 - DEVRO PLC
29th Nov 202212:47 pmRNSForm 8.3 - Devro plc
29th Nov 202211:23 amGNWForm 8.3 - [Devro plc - 28 11 2022] - (CGWL)
29th Nov 202211:15 amRNSForm 8.3 - Devro Plc
29th Nov 20229:58 amRNSForm 8.5 (EPT/RI) - Devro PLC
29th Nov 20229:45 amRNSForm 8.5 (EPT/RI)-Devro plc
29th Nov 20228:19 amRNSForm 8.3 - Devro PLC Amendment
28th Nov 20224:36 pmRNSForm 8.3 -Devro plc - Amendment
28th Nov 20223:21 pmRNSForm 8.3 - Devro Plc
28th Nov 20223:20 pmRNSForm 8.3 - Devro plc
28th Nov 20223:14 pmRNSForm 8.3 - Devro PLC
28th Nov 20223:03 pmRNSForm 8.3 - Devro plc
28th Nov 20222:59 pmRNSForm 8.3 - Devro PLC
28th Nov 20222:27 pmRNSForm 8.3 - Devro plc
28th Nov 20222:04 pmRNSForm 8.3 - Devro Plc
28th Nov 20221:45 pmRNSForm 8.3 - Devro PLC (closing postion)
28th Nov 20221:27 pmEQSForm 8.3 - The Vanguard Group, Inc.: Devro plc
28th Nov 20221:13 pmRNSForm 8.3 - Devro plc
28th Nov 202212:50 pmRNSForm 8.3 - DEVRO PLC
28th Nov 202212:06 pmRNSForm 8.3 - Devro Plc
28th Nov 202212:01 pmRNSForm 8.3 - Devro Plc
28th Nov 202211:03 amBUSForm 8.3 - Devro plc
28th Nov 202210:51 amRNSForm 8.3 - Devro PLC
28th Nov 202210:39 amGNWForm 8.3 - [DEVRO PLC 25 11 2022] - CGWL
28th Nov 202210:29 amRNSForm 8.5 (EPT/RI) - Devro PLC
28th Nov 20229:18 amRNSForm 8.5 (EPT/NON-RI)-Devro plc
28th Nov 20229:16 amRNSForm 8.5 (EPT/RI)-Devro plc
25th Nov 20222:48 pmEQSForm 8.3 - Maitland Institutional Services Limited: Re Devro plc
25th Nov 202211:35 amGNWDimensional Fund Advisors Ltd. : Form 8.3 - DEVRO PLC - Ordinary Shares
25th Nov 202210:51 amRNSForm 8.3 - Devro PLC
25th Nov 20229:31 amRNSForm 8.3 - Devro plc
25th Nov 20227:01 amRNSTrading Update
25th Nov 20227:00 amRNSRECOMMENDED CASH ACQUISITION
30th Sep 20222:41 pmRNSBLOCK LISTING SIX MONTHLY RETURN
12th Sep 20224:22 pmRNSHolding(s) in Company
2nd Aug 20227:00 amRNSHalf-year Report
29th Jul 20224:35 pmRNSDirector/PDMR Shareholding
27th Jul 20225:38 pmRNSDirector/PDMR Shareholding
11th May 202212:13 pmRNSDirector/PDMR Shareholding
29th Apr 20223:25 pmRNSTotal Voting Rights and Share Capital
28th Apr 20223:51 pmRNSResult of AGM
28th Apr 20227:00 amRNSAGM Trading Update
14th Apr 20222:22 pmRNSDirector/PDMR Shareholding
13th Apr 20226:10 pmRNSDirector/PDMR Shareholding
13th Apr 20227:00 amRNSHolding(s) in Company
6th Apr 202212:46 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.